Research location
Natal
Rio Grande do Norte, Brazil
Advertisement
Research activity in Natal
Rio Grande do Norte, BrazilCureCurrent currently publishes aggregate city-level research activity for this location: 134 trials and 136 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Natal
134 linked trials · page 2 of 3Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)NCT06117774 · 2024-02-20 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of TreatmentNCT06105632 · 2024-01-09 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)NCT06077760 · 2023-12-06 · 1 site observation
ACTIVE_NOT_RECRUITING
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)NCT06074588 · 2023-11-12 · 1 site observation
ACTIVE_NOT_RECRUITING
Safety, Tolerability and Antidepressant Effects of DMT in Patients With DepressionNCT06094907 · 2023-10-09 · 1 site observation
COMPLETED
Candesartan Cilexetil + Chlorthalidone + Amlodipine Versus Exforge HCT®️ for Systemic Arterial HypertensionNCT05920005 · 2023-08-22 · 1 site observation
COMPLETED
A Global Record of Patients With Anal Squamous Cell Carcinoma With and Without HIV InfectionNCT05328765 · 2023-06-09 · 2 site observations
COMPLETED
Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung CancerNCT05740566 · 2023-05-31 · 1 site observation
ACTIVE_NOT_RECRUITING
Amivantamab, Lazertinib, and Pemetrexed for First-line Treatment of Recurrent/Metastatic Non-small Cell Lung Cancers With Epidermal Growth Factor Receptor MutationsNCT05299125 · 2023-05-24 · 1 site observation
COMPLETED
A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local TherapiesNCT05794906 · 2023-04-03 · 1 site observation
ACTIVE_NOT_RECRUITING
Onco-Genomas Brasil: Mapping Breast and Prostate Cancer in the Brazilian Public Health SystemNCT05306600 · 2022-11-09 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)NCT05342636 · 2022-07-27 · 1 site observation
COMPLETED
Roll-over Study to Allow Continued Access to RibociclibNCT05161195 · 2022-07-07 · 1 site observation
ACTIVE_NOT_RECRUITING
Dose Ranging Study of Amlitelimab in Adult Participants With Moderate-to-severe AsthmaNCT05421598 · 2022-06-30 · 1 site observation
COMPLETED
Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007)NCT05226598 · 2022-03-24 · 1 site observation
TERMINATED
A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)NCT05239728 · 2022-03-15 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast CancerNCT05132582 · 2022-03-07 · 1 site observation
ACTIVE_NOT_RECRUITING
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)NCT05173987 · 2022-02-03 · 1 site observation
ACTIVE_NOT_RECRUITING
Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).NCT05116189 · 2021-12-13 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)NCT04736706 · 2021-04-14 · 1 site observation
ACTIVE_NOT_RECRUITING
Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003)NCT04738487 · 2021-04-07 · 1 site observation
TERMINATED
Intensified Chemo-immuno-radiotherapy With Durvalumab for Stage III Non-Small Cell Lung CancersNCT04230408 · 2021-03-05 · 1 site observation
COMPLETED
Darolutamide in Addition to ADT Versus ADT in Metastatic Hormone-sensitive Prostate CancerNCT04736199 · 2021-02-23 · 1 site observation
COMPLETED
A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)NCT04623775 · 2021-02-17 · 1 site observation
COMPLETED
A Study of Pembrolizumab (MK-3475) Plus Carboplatin and Paclitaxel as First-line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (MK-3475-B10/KEYNOTE B10)NCT04489888 · 2020-10-27 · 1 site observation
COMPLETED
Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLCNCT04524689 · 2020-10-26 · 1 site observation
TERMINATED
Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)NCT04246177 · 2020-05-22 · 1 site observation
TERMINATED
Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)NCT04221945 · 2020-05-12 · 1 site observation
COMPLETED
Patient Journey With Advanced Lung Cancer Positive for ALK Fusion in BrazilNCT04947683 · 2020-04-06 · 1 site observation
COMPLETED
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast CancerNCT03937154 · 2020-02-26 · 1 site observation
ACTIVE_NOT_RECRUITING
SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer PatientsNCT04154956 · 2020-02-06 · 1 site observation
TERMINATED
A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate CancerNCT04100018 · 2020-02-06 · 1 site observation
COMPLETED
Safety and Immunogenicity of a Tetravalent Dengue Vaccine in HIV-Positive AdultsNCT02741128 · 2019-11-06 · 1 site observation
COMPLETED
Real World Study of Biosimilar Trastuzumab in Her2 Positive Breast CancerNCT03892655 · 2019-10-07 · 1 site observation
ACTIVE_NOT_RECRUITING
Sentinel Lymph Node Biopsy Versus no Axillary Surgery in Early Breast CancerNCT05315154 · 2019-10-02 · 1 site observation
ACTIVE_NOT_RECRUITING
Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)NCT03834493 · 2019-07-28 · 1 site observation
TERMINATED
Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast CancerNCT03822468 · 2019-06-11 · 1 site observation
COMPLETED
Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)NCT03765918 · 2018-12-17 · 1 site observation
ACTIVE_NOT_RECRUITING
Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789)NCT03515837 · 2018-06-29 · 1 site observation
COMPLETED
Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)NCT03425643 · 2018-04-24 · 1 site observation
ACTIVE_NOT_RECRUITING
Ai Chi Method for Children With AsthmaNCT03392129 · 2017-12-20 · 1 site observation
UNKNOWN
Non Invasive Ventilation on Peripheral Muscle Function and Aerobic PerformanceNCT05417503 · 2017-12-01 · 1 site observation
COMPLETED
Study of Abiraterone Acetate Plus ADT Versus APALUTAMIDE Versus Abiraterone and APALUTAMIDE in Patients With Advanced Prostate Cancer With Non-castrate Testosterone LevelsNCT02867020 · 2017-10-11 · 1 site observation
COMPLETED
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDSNCT03141918 · 2017-09-08 · 1 site observation
COMPLETED
A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLCNCT03215706 · 2017-08-24 · 1 site observation
COMPLETED
Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate CancerNCT03072238 · 2017-06-30 · 1 site observation
COMPLETED
Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564)NCT03142334 · 2017-06-09 · 1 site observation
COMPLETED
A Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate CancerNCT03085095 · 2017-04-18 · 1 site observation
COMPLETED
Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE)NCT03061812 · 2017-04-11 · 1 site observation
COMPLETED
Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412)NCT03040999 · 2017-04-05 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.